Cash Flow Statement

Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt repayments

Daily Values

Growth Metrics

Others

Barinthus Biotherapeutics (BRNS) Other financing activities (2020 - 2021)

Barinthus Biotherapeutics (BRNS) has disclosed Other financing activities for 2 consecutive years, with $1.9 million as the latest value for Q4 2021.

For Q4 2021, Other financing activities rose 4951.35% year-over-year to $1.9 million; the TTM value through Dec 2021 reached $2.2 million, changed N/A, while the annual FY2021 figure was $2.2 million, 3698.25% up from the prior year.
Other financing activities hit $1.9 million in Q4 2021 for Barinthus Biotherapeutics, up from $274000.0 in the prior quarter.
Across five years, Other financing activities topped out at $1.9 million in Q4 2021 and bottomed at $22000.0 in Q1 2021.